Wound Care: Medicare Audits & The Skin Substitute Surge

Federal contractors – Recovery Audit Contractors (RACs) and Unified Program Integrity Contractors (UPICs) – have increasingly targeted wound care claims, particularly involving expensive skin substitutes billed under Medicare Part B.

In 2023 alone, over $1.6 billion was spent on these products, prompting heightened audit activity from Qlarant, Novitas, and others. This intense scrutiny stems from concerns about clinical efficacy, appropriate use, and billing integrity.

Why Auditors Flag Skin Grafts as “Not Medically Necessary”

Auditors frequently argue that skin grafts or tissue products lack medical necessity, based on Medicare’s definitions in CMS IOM 100‑08, Chapter 13, §13.5.1 and applicable Local Coverage Determinations (LCDs).

Common denial rationales include:

• Failure to document at least four weeks of prior conservative care (such as dressings, offloading, antibiotics, physical therapy, or splints) that failed before applying a skin substitute;
• Exceeding allowable applications or duration, when LCDs limit use, for example, skin substitute applications are limited to a certain number within a 12‑week period;
• Use of products deemed investigational, off‑label, or used in a non‑homologous manner under Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) guidelines;
• Allegations of excessive units or reapplications without documented improvement, or use of expensive products without justification; and
• Anti‑kickback concerns, including rebate agreements or manufacturer marketing influence that could bias product choice.

Provider Appeals & Favorable Case Stories

Still, experienced providers have successfully overturned denials, even for costly graft products, by carefully appealing UPIC and RAC decisions using regulation and case documentation citation.

A wound‑care provider audited by a UPIC was denied claims for a stage 4 sacral pressure ulcer, despite excellent documentation. The auditor asserted that the treatment exceeded 12 weeks. The provider appealed, showing that the first graft application began in March 2023 and ended in May, all within 12 weeks, even though wound care began months earlier.

The UPIC misread LCD language: the 12‑week limit applies only to graft applications, not total wound care duration. On appeal to the Medicare Administrative Contractor (MAC), documentation supported that medical necessity rules were correctly interpreted, and the claim was eventually reversed.

In another appeal, a UPIC denied graft claims, arguing the product was “not approved as a skin substitute,” but merely a dressing – even though the product appeared on a pending approved LCD list. At redetermination and Qualified Independent Contractor (QIC) levels, the provider showed that at the time of service, the product was on Medicare’s approved skin substitute list. The MAC agreed, and coverage was restored. This emphasizes the importance of quoting the exact LCD in effect at time of service.

Regulatory & Legal Support

Medicare IOM 100‑08, Chapter 13, §13.5.1 defines “reasonable and necessary,” emphasizing documentation of standard care failure and specific treatment rationale.

LCD L36690 (for cellular and tissue‑based products) requires documentation of at least four weeks of unsuccessful conservative care, patient condition specifics, and why a particular graft product was selected.

Many appeals hinge upon whether the provider tracked application count and duration, consistent with later‑effective LCD thresholds, even if the LCD later changed.

RAC appeals follow the five‑level appeal process (Redetermination, Reconsideration, ALJ hearing, MIC, and federal court) per the Providers’ Bill of Rights, with thresholds for amount in controversy at ALJ and judicial levels (often $1,500+ for ALJ).

Best Practices & Risks to Avoid

Based on these case outcomes and regulatory analysis, here’s what successful providers do:

• Chart detailed conservative treatment attempts, with dates and patient response, to support medical necessity under the LCD;
• Track graft application counts and timeline, to ensure that you are not exceeding per‑patient limits (e.g. 8–10 applications or 12‑week window);
• Use only covered products, ensuring that at time of treatment the product is listed in the LCD or officially approved;
• Avoid rebate or kickback arrangements, and have documentation of invoice prices versus Medicare payments, as UPICs are known to review rebate agreements and invoices; and
• Consider proactive internal audits of graft billing codes and refund overpayments voluntarily, if necessary; cover false claims risk.

Conclusion

Skin substitute grafts can be medically necessary – even when highly expensive – if they are used within LCD guidelines, after failed conservative care, and with full documentation of patient outcomes and rationale. UPIC and RAC auditors frequently deny these claims based on misinterpretation of LCD language, insufficient documentation, or concerns over product coverage. But providers that carefully appeal – invoking specific regulatory provisions (IOM §13.5.1, LCD L36690), backed up by detailed wound‑care timelines and documentation – have definitively overturned denials and preserved reimbursement.